Abstract
Background: Diabetes is a metabolic disorder, whose incidences are increasing day by day. Various classes of anti-diabetic drugs are clinically approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus, but unfortunately, none of them is able to treat this condition. Thus, the exploration of novel mechanistic pathways of existing molecules may help to develop more safe and effective anti-diabetic agents. Sodium orthovanadate is a well known common laboratory agent used to preserve the protein tyrosyl phosphorylation state of the protein.
Methods: The data related to sodium orthovanadate and diabetes mellitus has been collected from Pubmed.
Results: Various reports have indicated the potential of sodium orthovanadate as Protein Tyrosine Phosphatase (PTP1B) inhibitors which play an important role in the pathogenesis of diabetes. However, safety of Sodium orthovanadate is still questionable.
Conclusion: The sodium orthovanadate could be developed as an anti-diabetic agent. However, further studies are required to confirm its safety profile in the treatment of diabetes mellitus before starting a clinical trial.
Keywords: Diabetes mellitus, sodium orthovanadate, PTP1B, phosphorylation, safety, efficacy.
[1]
Deepthi B, Sowjanya K, Lidiya B, Bhargavi RS, Babu PS. A modern review of diabetes mellitus: an annihilatory metabolic disorder. J In Silico In Vitro Pharmacol 2017; 3(1): 1-5.
[2]
Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-a devastating metabolic disorder. Asian J Biomed Pharm 2015; 4(40): 1-7.
[3]
Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: A mini review. Curr Diabetes Rev 2017; 13(1): 3-10.
[5]
Himaja J, Suresha BS, Daniel NG, Kurian L. Assessment of prevalence and drug prescribing pattern of type-II diabetes mellitus 2016; 5(8): 1528-41.
[6]
Bhowmick A, Banu S. Therapeutic targets of type 2 diabetes: an overview. MOJ Drug Des Develop Ther 2017; 1(3): 1-6.
[7]
Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012; 156(3): 218-31.
[8]
Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med 2016; 33(4): 511-4.
[9]
Vieira MNe, Silva NM, Ferreira ST, De Felice FG. Protein tyrosine phosphatase 1B (PTP1B): A potential target for Alzheimer’s therapy? Front Aging Neurosci 2017; 9(7): 1-9.
[10]
Jeon YM, Lee S, Kim S, et al. Neuroprotective effects of protein tyrosine phosphatase 1B inhibition against ER stress-induced toxicity. Mol Cells 2017; 40(4): 280-90.
[11]
Thiebaut PA, Besnier M, Gomez E, Richard V. Role of protein tyrosine phosphatase 1B in cardiovascular diseases. J Mol Cell Cardiol 2016; 101: 50-7.
[12]
Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem 1988; 263(14): 6722-30.
[13]
Krishnan N, Konidaris KF, Gasser G, Tonks NK. A potent, selective and orally bioavailable inhibitor of the protein tyrosine phosphatase PTP1B improves insulin and leptin signalling in animal models. J Biol Chem 2018; 293(5): 1517-25.
[14]
Bakke J, Haj FG. Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin Cell Dev Biol 2015; 37: 58-65.
[15]
Herre DJ, Norman JB, Anderson R, Tremblay ML, Huby AC, De Chantemèle EJ. Deletion of protein tyrosine phosphatase 1B (PTP1B) enhances endothelial cyclooxygenase 2 expression and protects mice from type 1 diabetes-induced endothelial dysfunction. PLoS One 2015; 10(5): 1-15.
[16]
Sun W, Zhang B, Zheng H, et al. Trivaric acid, a new inhibitor of PTP1b with potent beneficial effect on diabetes. Life Sci 2017; 169: 52-64.
[17]
Tamrakar AK, Maurya CK, Rai AK. PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011–2014). Expert Opin Ther Pat 2014; 24(10): 1101-15.
[18]
Warren EB, Sillivan SE, Konradi C. Receptors and Second Messengers in the Basal Ganglia. In: Handbook of Behavioral Neuroscience. 2017; 25: pp. 555-81.
[19]
White MF. Receptor tyrosine kinases and the insulin signaling system. Principles Endocrinol Hormone Action 2017; pp. 1-34.
[20]
Anderie I, Schulz I, Schmid A. Direct interaction between ER membrane-bound PTP1B and its plasma membrane-anchored targets. Cell Signal 2007; 19(3): 582-92.
[21]
Khalil AA, Jameson MJ. Sodium orthovanadate inhibits proliferation and triggers apoptosis in oral squamous cell carcinoma in vitro. Biochemistry 2017; 82(2): 149-55.
[22]
Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985; 227(4693): 1474-7.
[23]
Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem 1987; 262: 6658-62.
[24]
Brichard SM, Desbuquois B, Girard J. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2. Mol Cell Endocrinol 1993; 91: 91-7.
[25]
Bendayan M, Gingras D. Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats. Diabetologia 1989; 32: 561-7.
[26]
Blondel O, Simon J, Chevalier B, Portha B. Impaired insulin action but normal insulin receptor activity in diabetic rat liver: Effect of vanadate. Am J Physiol 1990; 258: 459-67.
[27]
Goldfine AB, Simonson DC, Folli FR, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 1995; 80(11): 3311-20.
[28]
Gupta BL, Preet A, Baquer NZ. Protective effects of sodium orthovanadate in diabetic reticulocytes and ageing red blood cells of Wistar rats. J Biosci 2004; 29(1): 73-9.
[29]
Yadav UC, Moorthy K, Baquer NZ. Effects of sodium-orthovanadate and Trigonellafoenum-graecum seeds on hepatic and renal lipogenic enzymes and lipid profile during alloxan diabetes. J Biosci 2004; 29(1): 81-91.
[30]
Kumar P, Taha A, Kumar N, Kumar V, Baquer NZ. Sodium orthovanadate and Trigonella foenumgraecum prevents neuronal parameters decline and impaired glucose homeostasis in alloxan diabetic rats. Prague Med Rep 2015; 116(2): 122-38.
[31]
Domingo JL, Gómez M. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research. Food Chem Toxicol 2016; 95: 137-41.
[32]
Jiang P, Dong Z, Ma B, Ni Z, Duan H, Li X, et al. Effect of vanadyl rosiglitazone, a new insulin-mimetic vanadium complexes, on glucose homeostasis of diabetic mice. Appl Biochem Biotechnol 2016; 180(5): 841-51.
[33]
Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation. Mol Cell Biochem 1995; 153: 233-40.
[34]
Zaporowska H, Wasilewski W. Some selected haematological indices in Wistar rats in the vanadium-ethanol interaction. Comp Biochem Physiol 1990; 96: 33-7.
[35]
Zaporowska H, Wasilewski W. Haematological results of vanadium intoxication in Wistar rats. Comp Biochem Physiol 1992; 101: 57-61.
[36]
Sanchez DJ, Colomina MT, Domingo JL. Effects of vanadium on activity and learning in rats. Physiol Behav 1998; 63: 345-50.
[37]
De la Torre A, Granero S, Mayayo E, Corbella J, Domingo JL. Effect of age on vanadium nephrotoxicity in rats. Toxicol Lett 1999; 105: 75-82.
[38]
Zwolak I. Vanadium carcinogenic, immunotoxic and neurotoxic effects: a review of in vitro studies. Toxicol Mech Methods 2014; 24: 1-12.
[39]
Sakurai H. Vanadium distribution in rats and DNA cleavage by vanadyl complex: implication for vanadium toxicity and biological effects. Environ Health Perspect 1994; 102: 35-6.
[40]
Thompson KH, Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I. J Inorg Biochem 2006; 100: 1925-35.
[41]
Akesis Pharmaceuticals Discontinues Sole Clinical Development
Program and Announces Intent to File for Chapter 7 Bankruptcy,
January 21, 2009. Akesis Pharmaceuticals Inc. available at: http://wwwevaluategroup.com/Universal/ View.aspx?type1/4Story&id1/4179437
Article Metrics
40
8
2
1